Prelude Therapeutics (PRLD)

• Market cap: $67.4M
• 1 day: -11.85%
• 5 days: -24.68%
• 1 month: -17.36%
• 3 months: 38.86%
• 6 months: 55.7%
• Year to date: -4.8%
• 1 year: -6.3%
• 5 years: -97.13%
• 10 years: -95.46%
• Sector: Healthcare
• Industry: Biotechnology

About: Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Employees: 131